奥锐特：产品取得注册证

Group 1 - The core point of the article is that Aorite Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for a new drug registration certificate for a combination packaging of estradiol tablets and estradiol-dydrogesterone tablets [1] - Aorite's revenue composition for the first half of 2025 is as follows: 85.12% from self-produced raw materials and intermediates, 11.64% from formulations, 2.74% from trade, and 0.5% from other businesses [1] - As of the report date, Aorite's market capitalization is 8.9 billion yuan [1] Group 2 - The article also mentions that another company, identified by its stock code 688496, is under investigation by the China Securities Regulatory Commission due to a significant loss exceeding 100 million yuan shortly after its IPO, with its main customer reducing purchases [1]